These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24493312)

  • 1. The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas.
    Soldini D; Georgis A; Montagna C; Schüffler PJ; Martin V; Curioni-Fontecedro A; Martinez A; Tinguely M
    Hematol Oncol; 2014 Sep; 32(3):120-5. PubMed ID: 24493312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
    Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
    Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
    Gebauer N; Bernard V; Feller AC; Merz H
    Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.
    Rohde M; Bonn BR; Zimmermann M; Lange J; Möricke A; Klapper W; Oschlies I; Szczepanowski M; Nagel I; Schrappe M; ; ; Loeffler M; Siebert R; Reiter A; Burkhardt B
    Haematologica; 2017 Jun; 102(6):1091-1098. PubMed ID: 28209658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
    Petrich AM; Nabhan C; Smith SM
    Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
    Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
    Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of inhibitor of DNA binding 3 mutational variants in mature aggressive B-cell lymphoma.
    Szczepanowski M; Masqué-Soler N; Schlesner M; Haake A; Richter J; Wagener R; Burkhardt B; Kreuz M; Siebert R; ; Klapper W
    Haematologica; 2016 Jun; 101(6):e259-61. PubMed ID: 26992947
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients.
    Lu B; Zhou C; Yang W; Huang H; Gao Z; He Y; Liu H; Zhou X; Gong L
    Leuk Lymphoma; 2011 Dec; 52(12):2356-64. PubMed ID: 21740296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas.
    Pittaluga S; Ayoubi TA; Wlodarska I; Stul M; Cassiman JJ; Mecucci C; Van Den Berghe H; Van De Ven WJ; De Wolf-Peeters C
    J Pathol; 1996 Jun; 179(2):145-50. PubMed ID: 8758205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.
    Menter T; Medani H; Ahmad R; Flora R; Trivedi P; Reid A; Naresh KN
    Br J Haematol; 2017 Nov; 179(4):681-684. PubMed ID: 27447126
    [No Abstract]   [Full Text] [Related]  

  • 16. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.
    Soldini D; Montagna C; Schüffler P; Martin V; Georgis A; Thiesler T; Curioni-Fontecedro A; Went P; Bosshard G; Dehler S; Mazzuchelli L; Tinguely M
    Ann Oncol; 2013 Jan; 24(1):193-201. PubMed ID: 22967991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.
    Haralambieva E; Boerma EJ; van Imhoff GW; Rosati S; Schuuring E; Müller-Hermelink HK; Kluin PM; Ott G
    Am J Surg Pathol; 2005 Aug; 29(8):1086-94. PubMed ID: 16006805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
    Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
    Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
    Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
    N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of "Double Hit" Lymphomas Using Updated WHO Criteria: Insights From Routine MYC Immunohistochemistry in 272 Consecutive Cases of Aggressive B-Cell Lymphomas.
    Sakr H; Cook JR
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):410-415. PubMed ID: 29629947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.